EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Randomisierte kontrollierte StudieVergleichsstudie

Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study

Ling-Ming Tseng, Fang Ming Chen, Shou-Tung Chen, Fiona Tsui-Fen Cheng, Tsu-Yi Chao, Ming-Shen Dai, Woei-Yau Kao, Ming-Hsin Yeh, Dar-Ren Chen, Liang-Chih Liu, Hewi Chung Wang, Hong-Tai Chang und 5 weitere

Oncology Research and Treatment · 19.07.2024 · 47 (10) · 484-495

DOI: 10.1159/000540369 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology Research and Treatment, online erschienen am 19.07.2024. Verfasst von Ling-Ming Tseng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Breast Neoplasms, Quality of Life, Polyethylene Glycols, Epirubicin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This multicenter, phase II randomized, non-inferiority study reports from the first prospective two-armed randomized control trial that compared the efficacy, safety, and quality of life (QoL) of pegylated liposomal doxorubicin (PLD)-based and epirubicin-based as adjuvant chemotherapy for stage I-II human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

Methods

Patients with stage I/II HER2-negative breast cancer received PLD (37.5 mg/m2, Q3W, 5 cycles, LC arm) plus cyclophosphamide (600 mg/m2) or epirubicin (90 mg/m2, Q3W, 4 cycles, EC arm) plus cyclophosphamide (600 mg/m2). Randomization was stratified by lymph node and ER and PR status. The primary endpoint was disease-free survival (DFS), and secondary endpoints were overall survival (OS), safety profiles, and QoL. QoL was assessed using the EORTC-QLQ-C30 and QLQ-BR23 questionnaires.

Results

A total of 256 patients were assigned to LC (n = 148) and EC (n = 108). There was no difference in 5-year DFS and OS rate between the two groups. LC-based adjuvant regimens had significantly less alopecia and low-grade 3–4 hematologic adverse events (AEs). Significantly improved QoL was observed in the LC arm during and after treatment for symptoms including fatigue, nausea and vomiting, and systemic therapy side effects.

Conclusion

Comparable efficacy and safety between adjuvant PLD and epirubicin for stage I-II HER2-negative breast cancer was observed. There was no difference in the 5-year DFS and OS rates between the two treatment arms. However, low-grade 3–4 AEs and a trend of favorable QoL symptom scales were observed in the LC arm, suggesting that PLD-containing regimen could become a new standard treatment for early-stage HER2-negative breast cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsQuality of LifePolyethylene GlycolsEpirubicinDoxorubicinAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideErb-b2 Receptor Tyrosine KinasesHumansFemaleMiddle AgedAdultProspective StudiesAgedTreatment OutcomeNeoplasm StagingChemotherapy, Adjuvant

Stichwörter der Autor:innen

Disease-free survivalEpirubicinHER2-negative breast cancerOverall survivalPegylated liposomal doxorubicinQuality of life

Substanzen

Polyethylene GlycolsEpirubicinDoxorubicinCyclophosphamideErb-b2 Receptor Tyrosine Kinasesliposomal doxorubicinERBB2 protein, human

Autor:innen und Institutionen

  • Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Chun-Ho Memorial Hospital, Kaohsiung, Taiwan.
  • Department of Surgery, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
  • Department of Surgery, Faculty and College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua City, Taiwan.

Zitieren

APA

Tseng, L. M., Chen, F. M., Chen, S. T., Cheng, F. T., Chao, T. Y., Dai, M. S., Kao, W. Y., Yeh, M. H., Chen, D. R., Liu, L. C., Wang, H. C., Chang, H. T., Wang, B. W., Yu, J. C., Chen, S. C., Liao, G. S., & Hou, M. F. (2024). Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study. Oncology Research and Treatment, 47(10), 484-495. https://doi.org/10.1159/000540369

Vancouver

Tseng LM, Chen FM, Chen ST, Cheng FT, Chao TY, Dai MS, et al. Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study. Oncology Research and Treatment. 2024;47(10):484-495. doi:10.1159/000540369

BibTeX
@article{Tseng2024,
  author = {Tseng, Ling-Ming and Chen, Fang Ming and Chen, Shou-Tung and Cheng, Fiona Tsui-Fen and Chao, Tsu-Yi and Dai, Ming-Shen and Kao, Woei-Yau and Yeh, Ming-Hsin and Chen, Dar-Ren and Liu, Liang-Chih and Wang, Hewi Chung and Chang, Hong-Tai and Wang, Being Whey and Yu, Jyh-Cherng and Chen, Shin Cheh and Liao, Guo-Shiou and Hou, Ming-Feng},
  title = {Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study},
  journal = {Oncology Research and Treatment},
  year = {2024},
  volume = {47},
  number = {10},
  pages = {484--495},
  doi = {10.1159/000540369}
}
Kostenlos starten →